{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T05:57:03Z","timestamp":1656050223785},"reference-count":49,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej11-0144","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T22:57:39Z","timestamp":1369868259000},"page":"1035-1045","source":"Crossref","is-referenced-by-count":2,"title":["A novel mechanism for the inhibition of type 2 iodothyronine deiodinase by tumor necrosis factor \u03b1: involvement of proteasomal degradation"],"prefix":"10.1507","volume":"60","author":[{"given":"Takayuki","family":"Ogiwara","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Morimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Tsunekawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medicine and Molecular Sciences, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. Larsen PR (1996) Thyroid hormone transport, cellular uptake, metabolism and molecular action. In DeGroot LJ, Larsen PR and Hennermann G (ed) The thyroid and its disease. Churchill Livingstone, New York: 61-111."},{"key":"2","unstructured":"2. Leonard JL, Koehrle J (1996) Intracellular pathways of iodothyronine metabolism. In: LE Braverman & RD Utiger (ed) Werner and Ingbar\u2019s the thyroid: a fundamental and clinical text, edn 7. Lippincott-Raven, Philadelphia: 125-161."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Larsen PR (1996) Mammalian type 2 deiodinase sequences: finally, the end of the beginning. J Clin Invest<\/i> 98: <\/b>242-243.","DOI":"10.1172\/JCI118784"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, Mizuma H, Mori M (2001) Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology<\/i> 142: 2961-2967. <\/b>","DOI":"10.1210\/endo.142.7.8280"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Croteau W, Davey JC, Galton VA, St Germain DL (1996) Cloning of the mammalian type II iodothyronine deiodinase: A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J Clin Invest<\/i> 98: 405-417.","DOI":"10.1172\/JCI118806"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Salvatore D, Tibor B, Harney JW, Larsen PR (1996) Molecular biology and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology<\/i> 137: 3308-3315.","DOI":"10.1210\/endo.137.8.8754756"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M (1999) Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J Clin Endocrinol Metab<\/i> 84: 3293-3300.","DOI":"10.1210\/jc.84.9.3293"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mizuma H, Murakami M, Mori M (2001) Thyroid hormone activation in human vascular smooth muscle cells Expression of type II iodothyronine deiodinase. Circ Res<\/i> 88: 313-318.","DOI":"10.1161\/01.RES.88.3.313"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mooradian AD, Reed RL, Osterweil D, Schiffman R, Scuderi P (1990) Decreased serum triiodothyronine is associated with increased concentrations of tumor necrosis factor. J Clin Endocrinol Metab<\/i> 71: 1239-1242.","DOI":"10.1210\/jcem-71-5-1239"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab<\/i> 84: 151-164.","DOI":"10.1210\/jcem.84.1.5364"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yu J, Koenig RJ (2000) Regulation of hepatocyte thyroxine 5\u2019-deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome. J Biol Chem <\/i>275: 38296-38301.","DOI":"10.1074\/jbc.M004866200"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP (1990) Tumor necrosis factor: a putative mediator of the euthyroid syndrome in man. J Clin Endocrinol<\/i> Metab <\/i>71: 1567-1572.","DOI":"10.1210\/jcem-71-6-1567"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pang XP, Hershman JM, Mirell CJ, Pekary AE (1989) Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant tumor necrosis factor-alpha (cachectin). Endocrinology<\/i> 125: 76-84.","DOI":"10.1210\/endo-125-1-76"},{"key":"14","unstructured":"14. Takano T, Ito Y, Matuzaka F, Miya A, Kobayashi K, Yoshida H, Miyauchi A (2007) Quantitative measurement of telomerase reverse transcriptase, thyroglobilin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. Oncol Rep<\/i> 18; 715-720."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Samuels HH, Stanley F, Casanova J (1979) Depletion of L-3,5,3\u2019-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology<\/i> 105: 80-85.","DOI":"10.1210\/endo-105-1-80"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Leonard JL, Rosenberg IN (1980) Iodothyronine 5\u2019-deiodinase from rat kidney: substrate specificity and the 5\u2019-deiodination of reverse triiodothyronine. Endocrinology<\/i> 107: 1376-1383.","DOI":"10.1210\/endo-107-5-1376"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Murakami M, Tanaka K, Greer MA, Mori M (1988) Anterior pituitary type II thyroxine 5\u2019 deiodinase activity is not affected by lesions of the hypothalamic paraventricular nucleus which profoundly depress pituitary thyrotropin secretion. Endocrinology<\/i> 123: 1676-1681.","DOI":"10.1210\/endo-123-3-1676"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem<\/i> 72: 248-254.","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, De Herder WW, den Hollander JC, Krenning EP, Visser TJ (1998) Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab<\/i> 83: 2868-2874.","DOI":"10.1210\/jc.83.8.2868"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M (1996) Thymic hyperplasia in patients with Graves\u2019 disease. Identification of thyrotropin receptors in human thymus. J Clin Invest<\/i> 98: 2228-2234.","DOI":"10.1172\/JCI119032"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Steinsapir J, Harney J, Larsen PR (1998) Type 2 iodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes. J Clin Invest<\/i> 102: 1895-1899.","DOI":"10.1172\/JCI4672"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR (2000) Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme\u2019s active center. Endocrinology<\/i> 141: 1127-1135.","DOI":"10.1210\/endo.141.3.7355"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nagaya T, Fujieda M, Otsuka G, Yang JP, Okamoto T, Seo H (2000) A potential role of activated NF-\u03baB in the pathogenesis of euthyroid sick syndrome. J Clin Invest<\/i> 106: 393-402.","DOI":"10.1172\/JCI7771"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Fekete C, Gereben B, Doleschall M, Harney JW, Dora JM, Bianco AC, Sarkar S, Liposits Z, Rand W, Emerson C, Kacskovics I, Larsen PR, Lechan RM (2004) Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. Endocrinology<\/i> 145: 1649-1655.","DOI":"10.1210\/en.2003-1439"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zeöld A, Doleschall M, Haffner MC, Capelo LP, Menyhért J, Liposits Z, da Silva WS, Bianco AC, Kacskovics I, Fekete C, Gereben B (2006) Characterization of the nuclear factor-κB responsiveness of the human dio2<\/i> gene. Endocrinology<\/i> 147: 4419-4429.","DOI":"10.1210\/en.2005-1608"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Martin AG, San-Antonio B, Fresno M (2001) Regulation of nuclear factor κB transactivation. J Biol Chem<\/i> 276: 15840-15849.","DOI":"10.1074\/jbc.M011313200"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME (1997) Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem<\/i> 272: 21096-21103.","DOI":"10.1074\/jbc.272.34.21096"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Armstrong SJ, Wiberg M, Terenghi G, Kingham PJ (2008) Laminin activates NF-κB in Schwann cells to enhance neurite outgrowth. Neurosci Lett <\/i>439: 42-46.","DOI":"10.1016\/j.neulet.2008.04.091"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR (2000) Characterization of the 5\u2019-flanking and 5\u2019-untranslated regions of the cyclic adenosine 3\u2019,5\u2019-monophosphate-responsive human type 2 iodo-thyronine deiodinase gene. Endocrinology<\/i> 141: 229-237.","DOI":"10.1210\/endo.141.1.7282"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Beech SG, Walker SW, Dorrance AM, Arthur JR, Nicol F, Lee D, Beckett GJ (1993) The role of thyroidal type-I iodothyronine deiodinase in tri-iodothyronine production by human and sheep thyrocytes in primary culture. J Endocrinol <\/i>136: 361-370.","DOI":"10.1677\/joe.0.1360361"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Miyashita K, Murakami M, Iriuchijima T, Takeuchi T, Mori M (1995) Regulation of rat liver type 1 iodothyronine deiodinase mRNA levels by testosterone. Mol Cell Endocrinol<\/i> 115: 161-167.","DOI":"10.1016\/0303-7207(95)03689-X"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Chopra IJ, Sakane S, Teco GN (1991) A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses. J Clin Endocrinol Metab<\/i> 72: 1113-1116.","DOI":"10.1210\/jcem-72-5-1113"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pekary AE, Berg L, Santini F, Chopra I, Hershman JM (1994) Cytokines modulate type I iodothyronine deiodinase mRNA levels and enzyme activity in FRTL-5 rat thyroid cells. Mol Cell Endocrinol<\/i> 101: R31-35.","DOI":"10.1016\/0303-7207(94)90256-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hashimoto H, Igarashi N, Miyawaki T, Sato T (1995) Effects of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 on type I iodothyronine 5\u2019-deiodination in rat thyroid cell line, FRTL-5. J Interferon Cytokine Res<\/i> 15: 367-375.","DOI":"10.1089\/jir.1995.15.367"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Tang KT, Braverman LE, DeVito WJ (1995) Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5\u2019-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology<\/i> 136: 881-888.","DOI":"10.1210\/endo.136.3.7867596"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Fujii T, Sato K, Ozawa M, Kasono K, Imamura H, Kanaji Y, Tsushima T, Shizume K (1989) Effect of interleukin-1 (IL-1) on thyroid hormone metabolism in mice: stimulation by IL-1 of iodothyronine 5\u2019-deiodinating activity (type I) in the liver. Endocrinology<\/i> 124: 167-174.","DOI":"10.1210\/endo-124-1-167"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Baur A, Bauer K, Jarry H, Kohrle J (2000) Effects of proinflammatory cytokines on anterior pituitary 5\u2019-deiodinase type I and type II. J Endocrinol<\/i> 167: 505-515.","DOI":"10.1677\/joe.0.1670505"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Molnar I, Balazs C, Szegedi G, Sipka S (2002) Inhibition of type 2,5\u2019-deiodinase by tumor necrosis factor alpha, interleukin-6 and interferon gamma in human thyroid tissue. Immunol Lett<\/i> 80: 3-7.","DOI":"10.1016\/S0165-2478(01)00301-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. St. Germain DL, Galton VA, Hernandez (2009) A Minireview: Defining the Roles of the Iodothyronine Deiodinases: Current Concepts and Challenges. Endocrinology <\/i>150: 1097-1107.","DOI":"10.1210\/en.2008-1588"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ (2005) Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer <\/i>93: 774-780.","DOI":"10.1038\/sj.bjc.6602780"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren PO (1997) Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest<\/i> 99: 163-168.","DOI":"10.1172\/JCI119143"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC (2000) Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol<\/i> 14: 1697-1708.","DOI":"10.1210\/mend.14.11.0558"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Botero D, Gereben B, Goncalves C, De Jesus LA, Harney JW, Bianco AC (2002) Ubc6p and ubc7p are required for normal and substrate-induced endoplasmic reticulum-associated degradation of the human selenoprotein type 2 iodothyronine monodeiodinase. Mol Endocrinol<\/i> 16: 1999-2007.","DOI":"10.1210\/me.2002-0135"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Kim BW, Zavacki AM, Curcio-Morelli C, Dentice M, Harney JW, Larsen PR, Bianco AC (2003) Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl region of D2. Mol Endocrinol<\/i> 17: 2603-2612.","DOI":"10.1210\/me.2003-0082"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Llovera M, Garcia-Martinez C, Agell N (1997) TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun <\/i>230: 238-241.","DOI":"10.1006\/bbrc.1996.5827"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kikuchi H, Ozaki T, Furuya1 K, Hanamoto T, Nakanishi M, Yamamoto H, Yoshida K, Todo S, Nakagawara A (2006) NF-κB regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway. Oncogene <\/i>25: 7608-7617.","DOI":"10.1038\/sj.onc.1209748"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Medina EA, Afsari RR, Ravid T, CastilloSS, Erickson KL, Goldkorn T (2005) Tumor necrosis factor-α decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology<\/i> 146: 2726-2735.","DOI":"10.1210\/en.2004-1074"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Rodriguez-Perez A, Palos-Paz F, Kaptein E, Visser TJ, Dominguez-Gerpe L, Alvarez-Escudero J, Lado-Abeal J (2008) Identification of molecular mechanisms related to nonthyroidal illness syndrome in skeletal muscle and adipose tissue from patients with septic shock. Clin Endocrinol (Oxf)<\/i> 68: 821-827.","DOI":"10.1111\/j.1365-2265.2007.03102.x"},{"key":"49","unstructured":"49. Warner MH, Beckett GJ (2010) Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol<\/i> 205: 1-13."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/9\/60_EJ11-0144\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:10:24Z","timestamp":1618294224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/9\/60_EJ11-0144\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej11-0144","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}